KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Operations: 2016-2024

Historic Cash from Operations for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $295.1 million.

  • Amneal Pharmaceuticals' Cash from Operations fell 16.45% to $118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $327.8 million, marking a year-over-year increase of 4.77%. This contributed to the annual value of $295.1 million for FY2024, which is 14.61% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Cash from Operations stood at $295.1 million for FY2024, which was down 14.61% from $345.6 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Cash from Operations ranged from a high of $379.0 million in FY2020 and a low of $65.1 million during FY2022.
  • Moreover, its 3-year median value for Cash from Operations was $295.1 million (2024), whereas its average is $235.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 22,128.80% in 2020, then crashed by 73.08% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Operations (Yearly) stood at $379.0 million in 2020, then crashed by 36.20% to $241.8 million in 2021, then slumped by 73.08% to $65.1 million in 2022, then skyrocketed by 430.84% to $345.6 million in 2023, then declined by 14.61% to $295.1 million in 2024.